- 11 abstracts on Wegovy® and MASH to be presented at AASLD 2025.
- Presentations include post-hoc analyses of the ESSENCE trial.
- Data covers semaglutide 2.4 mg's effects on MASH and weight loss.
Overview
Novo Nordisk will present 11 abstracts at the 76th Annual American Association for the Study of Liver Diseases (AASLD) congress, The Liver Meeting® 2025, from November 7 to 11 in Washington D.C., U.S.
Key Data
The presentations will include clinical and real-world data on Wegovy® (semaglutide 2.4 mg) in metabolic dysfunction-associated steatohepatitis (MASH), focusing on weight loss and diverse patient populations.
ESSENCE Trial Insights
Post-hoc analyses of the ESSENCE trial will provide insights into the clinical effects of semaglutide 2.4 mg across different stages of MASH disease progression and within diverse population subgroups.
Additional Research
Real-world data will also be presented, evaluating the benefit of non-invasive tests (NITs) and exploring the prevalence of steatosis and liver fibrosis in patients with MASLD/MASH from non-hepatology centers in the USA and Europe.
